We are committed to the discovery and development of first-in-class, oral therapeutics for patients with autoimmune diseases

Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune disease. The Company’s lead product candidate, BT-11, is a small molecule that targets a novel immunometabolic pathway within the gastrointestinal tract, potentially providing a more effective treatment and an improved patient tolerability profile.

In January 2021, the Company reported initial results from its Phase 2 trial of BT-11 for patients with mild to moderate ulcerative colitis (UC). In the first half of 2021, Landos expects to initiate a Phase 3 trial of BT-11 in UC patients and plans to initiate a Phase 2 trial of BT-11 in moderate to severe Crohn’s disease (CD).

View More